Elanco Animal Health (ELAN) | Stock Overview & Key Data
Elanco Animal Health Performance Comparison
Stock Range
Today's Range
Low: $20.43
High: $20.91
on October 2, 2025
52 Week Range
Low: $8.02
High: $20.92
on April 17, 2025
on October 1, 2025
All-Time High: $37.61 on September 24, 2018
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$9.7B
EPS
0.88
P/E Ratio (TTM)
22.28
Forward P/E
20.86
P/B Ratio
1.44
PEG Ratio
-0.19
Div. Yield
N/A
ROE
6.83%
Beta
1.622
Debt to Equity
62.13
Financial Highlights
Profitability
Gross Margin
57.45%
Operating Margin
6.85%
Profit Margin
9.68%
Returns and Earnings
Return on Assets (TTM)
0.98%
Return on Equity (TTM)
6.83%
EBITDA
$843.0M
Net Income (TTM)
$434.0M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$9.07
Quarterly Revenue Growth (YoY)
4.80%
Quarterly Earnings Growth (YoY)
4.81%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Elanco Animal Health ELAN | 9.74B Mid-cap | 8.19% | 14.68% | 39.06% | 90.06% | 69.88% | 39.63% | 66.69% | -38.16% |
| Haleon Plc - ADR HLN | 41.72B Large-cap | 1.83% | -9.02% | -13.45% | -12.60% | -5.93% | -14.37% | 45.81% | 19.84% |
| United Therapeutics UTHR | 19.33B Large-cap | 4.24% | 9.54% | 50.21% | 42.01% | 23.10% | 24.59% | 114.46% | 326.34% |
| Regencell Bioscience RGC | 7.64B Mid-cap | 6.67% | 25.68% | 55.89% | 2,504.84% | 12,323.08% | 14,581.82% | 1,845.78% | 5,667.86% |
| Alkermes plc ALKS | 5.29B Mid-cap | 15.22% | 6.33% | 7.79% | -4.26% | 8.73% | 7.90% | 41.26% | 85.41% |
| Prestige Consumer PBH | 3.79B Mid-cap | 0.19% | -5.50% | -21.63% | -26.96% | -19.15% | -8.70% | 26.31% | 69.11% |
Ownership & Short Interest
Insider Ownership
1.03%
Institutional Ownership
109.83%
Shares Short
27M
Short Ratio
2.68
Short % of Shares Outstanding
7.62%
Average 10-Day Volume
5M
Average 90-Day Volume
9M
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is ELAN's 52-week high and low?
- In the last 52 weeks, Elanco Animal Health reached a high of $20.92 (on October 1, 2025) and a low of $8.02 (on April 17, 2025).
- What is the market cap and P/E ratio for ELAN?
- Curious about Elanco Animal Health's size and valuation? Its market capitalization stands at 9.74B. When it comes to valuation, the P/E ratio (trailing twelve months) is 22.28, and the forward P/E (looking ahead) is 20.86.
- Does ELAN pay dividends? If so, what's the yield?
- As for dividends, Elanco Animal Health isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Elanco Animal Health's main competitors or similar companies to consider before investing?
When looking at Elanco Animal Health, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Haleon Plc - ADR
HLN41.72B Healthcare Drug Manufacturers - Specialty & Generic -14.37% 45.81% United Therapeutics
UTHR19.33B Healthcare Drug Manufacturers - Specialty & Generic 24.59% 114.46% Regencell Bioscience
RGC7.64B Healthcare Drug Manufacturers - Specialty & Generic 14,581.82% 1,845.78% Alkermes plc
ALKS5.29B Healthcare Drug Manufacturers - Specialty & Generic 7.90% 41.26% Prestige Consumer
PBH3.79B Healthcare Drug Manufacturers - Specialty & Generic -8.70% 26.31% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Elanco Animal Health Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Elanco Animal Health's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 6.83%, the Debt to Equity ratio from the most recent quarter is 62.13, and its Gross Profit Margin stands at 57.45%.
- What is the recent revenue and earnings growth for ELAN?
- Looking at Elanco Animal Health's growth, its revenue over the trailing twelve months (TTM) was $4B. Compared to the same quarter last year (YoY), quarterly revenue grew by 4.80%, and quarterly earnings saw a YoY growth of 4.81%.
- How much of ELAN stock is held by insiders and institutions?
- Wondering who owns Elanco Animal Health stock? Company insiders (like executives and directors) hold about 1.03% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 109.83%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.